Skip to main navigation Skip to search Skip to main content

Osimertinib or platinum-pemetrexed in EGFR T790M-Positive lung cancer

  • T. S. Mok
  • , Y. L. Wu
  • , M. J. Ahn
  • , M. C. Garassino
  • , H. R. Kim
  • , S. S. Ramalingam
  • , F. A. Shepherd
  • , Y. He
  • , H. Akamatsu
  • , W. S.M.E. Theelen
  • , C. K. Lee
  • , M. Sebastian
  • , A. Templeton
  • , H. Mann
  • , M. Marotti
  • , S. Ghiorghiu
  • , V. A. Papadimitrakopoulou
  • Prince of Wales Hospital Hong Kong
  • Guangdong Academy of Medical Sciences
  • Sungkyunkwan University
  • IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
  • Yonsei University
  • Emory University
  • Princess Margaret Cancer Centre
  • Daping Hospital, the Third Military Medical University
  • Wakayama Medical University
  • Netherlands Cancer Institute
  • St. George Hospital
  • Goethe University Frankfurt
  • AstraZeneca
  • University of Texas MD Anderson Cancer Center

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Osimertinib or platinum-pemetrexed in EGFR T790M-Positive lung cancer'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science